← Back to the boardNews
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
Why it’s here: An FDA rejection of a novel cancer drug from a US biotech partnered with a Chinese drugmaker is biotech regulatory policy with a US-China angle, though the story is mainly a single-drug regulatory decision.
Item
5h agoSTATSTAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe FDA issued a complete rejection of Summit Therapeutics and Akeso's lung cancer drug ivonescimab because it did not show an overall survival benefit despite slowing disease progression.1 outletBiotech
About
- Food and Drug Administration